Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

Video

Do-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Related Content